Wednesday, Apr 24 2024 | Time 01:20 Hrs(IST)
image
Business EconomyPosted at: Oct 14 2020 12:36PM


Glenmark launches NINDANIB (Nintedanib) capsules for the treatment of pulmonary fibrosis in India

Mumbai, Oct 14 (UNI) Pharma Major, Glenmark Pharmaceuticals on Wednesday launched NINDANIB (Nintedanib 100 and 150 mg capsules) for the treatment of pulmonary fibrosis in India.
Glenmark being a leader in the area of respiratory has been amongst the first to launch the branded generic version at an affordable cost for the treatment of Pulmonary Fibrosis in India. This will provide patients a far more cost effective treatment option, and enable doctors to treat a wider patient population in the country.
Nintedanib is approved by the Indian drug regulator for the treatment of Idiopathic (unknown cause) Pulmonary Fibrosis (IPF). Since IPF is a progressive disease that gets worse over time, starting treatment early and continuing treatment are important to slow disease progression. A lower monthly treatment cost therefore becomes crucial to ensure patients adhere to prescribed treatment in the long term.
So far Nintedanib has been studied extensively in various controlled clinical trials that have established its efficacy and safety. In a recently published INBUILDtm trial, Nintedanib showed significantly lower annual rate of decline in FVC (Forced Vital Capacity) – a measure of lung health – with various progressive fibrosing interstitial lung diseases4.
Moreover, two clinical trials are being rolled out for to study the efficacy and safety of Nintedanib as a treatment of SARS-COV2 induced pulmonary fibrosis in Moderate to Severe COVID-19 patients.
''With limited treatment options available, interstitial lung diseases pose a significant treatment challenge in India. The high price of newer treatments and the pill burden of existing options only add to poor patient adherence.
By introducing NINDANIB, we hope to substantially reduce both the pill and cost burden for patients in India,''said Mr. Alok Malik, Group Vice President & Business Head, India Formulations.
''Glenmark continues to invent and innovate healthcare solutions that meet specific and often hard-to-address needs of patients in India and the world.” He added.
Pulmonary fibrosis (PF) is a respiratory condition characterized by the thickening and/or scarring of the lungs. This makes it difficult for oxygen to pass through the air sacs and into the bloodstream, causing symptoms such as shortness of breath and dry cough. The average survival rate in patients with IPF is poor, with only 20 to 30 percent of people surviving at least five years after diagnosis. The most frequent cause of death is respiratory failure.2 IPF
typically affects men over the age of 65 in India, and most people with IPF live only three to five years post diagnosis, if left untreated.
UNI JS GNK 1236
Please log in to get detailed story.
Tags: #Glenmark launches NINDANIB (Nintedanib) capsules for the treatment of pulmonary fibrosis in India
More News
Sensex ends in green; up 89 83 points

Sensex ends in green; up 89 83 points

23 Apr 2024 | 6:58 PM

Mumbai, April 23 (UNI) The stock market on Tuesday opened strong with 400 points up with all-round shopping but paired early gains towards end of the trading hour and closed at 73,738, about 90 points up from its previous close.

see more..

FHRAI seeks govt intervention to utilize increased FAR scheme for hotel industry expansion

23 Apr 2024 | 6:55 PM

New Delhi, Apr 23 (UNI) The apex association of hotels and restaurants FHRAI has approached the Government for resolution of long pending issue of not able to use the provision of increased Floor Area Ratio (FAR) saying this coming in the way to expanding the capacity and new hotel developments in Delhi.

see more..

23 Apr 2024 | 6:22 PM

New Delhi, Apr 23 (UNI) Telecom major Jio Infocomm, a wholly owned by Reliance Industries Limited, has increased its subscriber tally to 470.86 million at the end of December, 2023, up 8.76 per cent from its subscriber base of 432.92 million a year ago.

see more..

Kottayam-Kochi Rubber Market Rates

23 Apr 2024 | 6:11 PM

Kottayam, April 23 (UNI) Following were the Rubber Market rates announced by the Rubber Board here today per quintal.

see more..

Rupee marginally up 3 paise against USD

23 Apr 2024 | 4:37 PM

Mumbai, April 23 (UNI) The Rupee on Tuesday gained three paise to close at 83.34 against the USD on selling US Dollar by bankers and exporters, dealers at the Foreign exchange said.

see more..
image